Back to search

Switzerland· 55918004

Lumigan, 0.1 mg/ml, Augentropfen

A bimatoprost product containing bimatoprostum, registered in Switzerland by AbbVie AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 19 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC S01EE03

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedLumigan, 0.1 mg/ml, AugentropfenATCS01EE03REGISTER NO.55918004PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Bimatoprost is registered in 19 of 19 countries.

Countries holding a registration under ATC S01EE03 (bimatoprost), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 11 of them publish a price we can compare per daily dose

Bimatoprost · ATC S01EE03

19 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
bimatoprostum
Manufacturer
AbbVie AG
Country
Switzerland (CH)
ATC code
S01EE03
ATC class
Bimatoprost
Defined daily dose
0.1 ml, AT
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680559180045
    3 ml
    CHF 32.35

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

89 interactions on record for bimatoprost.

Graded by severity as the source publishes them — 89 info. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Bimatoprost · interactions on record

89 records

Interaction register. Grades as the source publishes them.

Same medicine, other countries

Bimatoprost in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bimatoprost products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Bima-Vision Sine, Bimato-Vision
  • Belgium · Bimatoprost Eg, Bimatoprost Eg (Eurogenerics)
  • Bulgaria · Бимаган, Биматопрост Абр
  • Cyprus · Bimatoprost Pharmathen, Birmost
  • Czechia · Bimatoprost Farmaprojects, Bimatoprost Olikla
  • Germany · Amiriox, Bimato-Vision
  • Denmark · Bimatoprost "hexal", Bimatoprost "stada"
  • Estonia · Elymbus
  • Spain · Amiriox, Bamixol
  • Finland · Bimatoprost, Bimatoprost Sandoz
  • France · Amiriox, Bimatoprost
  • United Kingdom (Northern Ireland) · Amiriox, Bimatoprost Alissa Healthcare Research
  • Greece · Birmost, Dacrysan
  • Croatia · Elymbus
  • Ireland · Elymbus, Eyreida
  • Iceland · Bimatoprost, Elymbus
  • Italy · Amiriox, Bialviz
  • Liechtenstein · Lumigan
  • Lithuania · Bimican, Bimifree
  • Luxembourg · Bimatoprost Eg, Bimatoprost Eg (Eurogenerics) Nv
  • Latvia · Bimican, Bimifre
  • Netherlands · Bimagan, Bimato-Vision
  • Norway · Bimaprez, Bimatoprost Hexal
  • Poland · Bimican, Bimifree
  • Portugal · Amiriox, Bimatoprost Stulln
  • Romania · Amiriox, Bimagan
  • Sweden · Bimaprez, Bimatoprost
  • Slovenia · Elymbus
  • Slovakia · Bimatoprost Olikla, Elymbus

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2d0df877-be9d-4683-8599-26552cfa04cb
GET /v1/drugs/2d0df877-be9d-4683-8599-26552cfa04cb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "bimatoprostum 0.1 mg",
  "valid_from": "2010-11-01",
  "limitations": null,
  "galenic_form": "Gtt Opht 0.1 mg/ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2010-11-01",
  "self_retention_pct": 10
}

See everything about bimatoprost.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.